Differences among formulary submission guidelines: implications for health technology assessment.
about
From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countriesDo different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions.Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries.PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE RECOMMENDATIONS IN AUSTRALIA.Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.
P2860
Differences among formulary submission guidelines: implications for health technology assessment.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Differences among formulary su ...... health technology assessment.
@en
Differences among formulary su ...... health technology assessment.
@nl
type
label
Differences among formulary su ...... health technology assessment.
@en
Differences among formulary su ...... health technology assessment.
@nl
prefLabel
Differences among formulary su ...... health technology assessment.
@en
Differences among formulary su ...... health technology assessment.
@nl
P2093
P1476
Differences among formulary su ...... health technology assessment.
@en
P2093
Catherine Copley-Merriman
Jeffrey Walter
Josephine Mauskopf
Julie Birt
Lee Bowman
Michael Drummond
P304
P356
10.1017/S0266462311000274
P577
2011-07-01T00:00:00Z